The Amarin Decision: Free Speech Or Truthiness?

Amarin, which makes the prescription fish oil product Vascepa, won a big victory last Friday in its ongoing battle against the FDA. The bottom line: a federal judge ruled that the FDA can’t restrict Amarin’s first amendment right to disseminate off-label information about Vascepa providing it is neither false nor misleading. (You can read a detailed description of the entire case on the FDA Law Blog.). The ruling basically affirms and slightly expands the 2012 Caronia ruling, which first broadened the right of free speech for pharma representatives. The judge in the Amarin case said that this right applies More…
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Amarin Caronia FDA Fish oil Vascepa Source Type: blogs